Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An announcement from Protalix ( (PLX) ) is now available.
On June 26, 2025, Protalix Biotherapeutics, Inc. held its Annual Meeting of Stockholders in Tel Aviv, Israel. During the meeting, stockholders elected eight board members, approved executive compensation on a non-binding basis, and ratified the appointment of Kesselman & Kesselman as the independent accounting firm for the fiscal year ending December 31, 2025.
The most recent analyst rating on (PLX) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Protalix stock, see the PLX Stock Forecast page.
Spark’s Take on PLX Stock
According to Spark, TipRanks’ AI Analyst, PLX is a Neutral.
The stock’s overall score is driven by significant improvements in financial performance and strong guidance from the earnings call. However, technical analysis indicates current bearish trends and valuation concerns, impacting the score negatively.
To see Spark’s full report on PLX stock, click here.
More about Protalix
Average Trading Volume: 911,976
Technical Sentiment Signal: Strong Sell
Current Market Cap: $112.2M
Learn more about PLX stock on TipRanks’ Stock Analysis page.